Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) (Cloric)
A Phase II Open-label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-risk AML, MDS or ALL.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69437
- Hôpital Edouard Herriot
-
Marseille, France, 13273
- Institut Paoli Calmettes
-
Nantes, France, 44093
- Nantes university hospital
-
Paris, France, 75475
- Hopital Saint Louis
-
Pessac, France, 33604
- CHU Haut-Lévêque
-
Strasbourg, France, 67098
- CHRU Hautepierre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 to 65
- For patients younger than 50 years, cons-indication for the use of a standard myeloablative conditioning (history of hematopoietic stem cell transplantation autologous or allogeneic, or the presence of co-morbidities or medical history making prohibitive in terms toxicity using chemotherapy and / or high dose radiotherapy as judged by the referring physician) - MDS, ALL or AML at high risk, WHO THE biphenotypic-Score <2
- Any primary diagnosis of high-risk MDS/AML or ALL eligible for a treatment by reduced intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-SCT)
- Suitable donor available (related or matched unrelated)
- Cardiac: LV Ejection Fraction ≥ 50% by MUGA or Echocardiogram.
- Pulmonary: FEV1 and FVC ≥ 50% predicted, and DLCO (corrected for hemoglobin) ≥ 50% of predicted
- Adequate renal and hepatic function
- Performance status: Karnofsky ≥ 70%
- Informed consent signed by patient prior to enrolment
Exclusion Criteria:
- Age <18
- Age >65
- Known hypersensitivity to clofarabine or excipients- Other hematologic malignancies than ALL, AML and MDS
- Patients with prior standard allogeneic HSCT with grade > 2 aGvHD
- Prior standard allogeneic transplantation if < 2 months
- Contra-indication to one of the drug of the RIC regimen .
- Patient with > 3 treatment lines prior to inclusion
- Pregnant or lactating females
- Patient HIV+, Hep B+, Hep C+- Uncontrolled systemic infection
- Performance Status Score ECOG > 2- Known central nervous system involvement with AML or ALL- Uncontrolled active infection of any kind or bleeding
- Any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo the agents included in the conditioning regimen.
- For patients younger than 50 years, possibly indicating a standard myeloablative conditioning
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Relapse rate at one year after allo-SCT using the Clofarabine+Busulfan +Thymoglobuline reduced intensity conditioning regimen (CBT regimen).
Time Frame: at one year
|
at one year
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Nucleic Acids, Nucleotides, and Nucleosides
- Hydrocarbons, Acyclic
- Hydrocarbons
- Purines
- Alkanes
- Alcohols
- Butylene Glycols
- Glycols
- Mesylates
- Alkanesulfonates
- Alkanesulfonic Acids
- Sulfonic Acids
- Sulfur Acids
- Nucleosides
- Arabinonucleosides
- Ribonucleotides
- Nucleotides
- Adenine Nucleotides
- Purine Nucleotides
- Clofarabine
- Busulfan
Other Study ID Numbers
Other Study ID Numbers
- BRD/08/07-J
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.